The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome
Open accessAbstract
Fragile X syndrome (FXS) is caused by loss of the FMR1 gene product FMRP (fragile X mental retardation protein), a repressor of mRNA translation. According to the metabotropic glutamate receptor (mGluR) theory of FXS, excessive protein synthesis downstream of mGluR5 activation causes the synaptic pathophysiology that underlies multiple aspects of FXS. Here, we use an in vitro assay of protein synthesis in the hippocampus of male Fmr1 knock-out (KO) mice to explore the molecular mechanisms involved in this core biochemical phenotype under conditions where aberrant synaptic physiology has been observed. We find that elevated basal protein synthesis in Fmr1 KO mice is selectively reduced to wild-type levels by acute inhibition of mGluR5 or ERK1/2, but not by inhibition of mTOR (mammalian target of rapamycin). The mGluR5-ERK1/2 pathway is not constitutively overactive in the Fmr1 KO, however, suggesting that mRNA translation is hypersensitive to basal ERK1/2 activation in the absence of FMRP. We find that hypersensitivity to ERK1/2 pathway activation also contributes to audiogenic seizure susceptibility in the Fmr1 KO. These results suggest that the ERK1/2 pathway, and other neurotransmitter systems that stimulate protein synthesis via ERK1/2, represent additional therapeutic targets for FXS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“have demonstrated that dampening mGluR5 signalling rescues protein synthesis and many of the classic outcome measures (TABLE 1) used in the mouse and fly models30–35.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“These findings are the basis of human clinical trials that aim to test the efficacy of mGluR5 antagonists for the treating Fragile X syndrome23,56–58.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [57]
In the citing paper
“These findings of deficient mGluR–LTD in mice with deletions in Tsc1 or Tsc2 are in contrast with Fmr1 knockout mice, which have increased mGluR–LTD and excessive protein synthesis57.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [57]
In the citing paper
“We found a small but significant increase in protein synthesis of both FMRP targets in the absence of functional FMRP, similar to results reported for Camk2a by Bear and colleagues in slice cultures (Osterweil et al., 2010), with no significant change in either overall protein synthesis or in the synthesis of the non-target PABP (Figure 6G and Figure S6).”
From FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism (2011) · cites this paper as Osterweil et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,103
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Self-citationHara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., BELHAM, C. M., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14484 · Cited by 1,370
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Self-citationBrown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109
Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression.
Huber, K., Kayser, M., & Bear, M. (2000) · Science · doi:10.1126/science.288.5469.1254 · Cited by 1,015
Self-citationCorrection of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Self-citationThe MEK/ERK cascade: From signaling specificity to diverse functions
Shaul, Y. D., & Seger, R. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.005 · Cited by 969
Research works printed but not linked: 1
- 10.1017/S0012162201002833 · DOI · Paper page
Cited by
Sorted by citations
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Advancing the understanding of autism disease mechanisms through genetics
de la Torre-Ubieta, L., Won, H., Stein, J. L., & Geschwind, D. H. (2016) · Nature Medicine · doi:10.1038/nm.4071 · Cited by 827
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Zoghbi, H. Y., & Bear, M. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009886 · Cited by 797
Self-citationActivity-dependent neuronal signalling and autism spectrum disorder
Ebert, D. H., & Greenberg, M. E. (2013) · Nature · doi:10.1038/nature11860 · Cited by 666
Mutations causing syndromic autism define an axis of synaptic pathophysiology
Auerbach, B. D., Osterweil, E. K., & Bear, M. F. (2011) · Nature · doi:10.1038/nature10658 · Cited by 592
Self-citationMolecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Self-citationThe translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491
Clement, J. P., Aceti, M., Creson, T. K., Ozkan, E. D., Shi, Y., Reish, N. J., Almonte, A. G., Miller, B. H., Wiltgen, B. J., Miller, C. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.045 · Cited by 385
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370
Self-citationDrug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citationLee, B., Lee, K., Panda, S., Gonzales-Rojas, R., Chong, A., Bugay, V., Park, H. M., Brenner, R., Murthy, N., & Lee, H. Y. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0252-8 · Cited by 361
Overview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 363
A synaptic perspective of fragile X syndrome and autism spectrum Disorders.
Bagni, C., & Zukin, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.041 · Cited by 326
Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., & Klann, E. (2012) · Neuron · doi:10.1016/j.neuron.2012.07.022 · Cited by 316
Dysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275
Fundamental Elements in Autism: From Neurogenesis and Neurite Growth to Synaptic Plasticity
Gilbert, J. P., & Man, H. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00359 · Cited by 286
Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome
Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259
Self-citationDisrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome
Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N.-P., Guo, W., Birnbaum, S. G., Hu, J.-H., Worley, P. F., Gibson, J. R., & Huber, K. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3033 · Cited by 251
Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249
Self-citationFragile X mental retardation protein and synaptic plasticity
Sidorov, M. S., Auerbach, B. D., & Bear, M. F. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-15 · Cited by 255
Self-citationOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230
Self-citationAn epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Translational control of mGluR-dependent long-term depression and object-place learning by eIF2α
Prisco, G. V. D., Huang, W., Buffington, S. A., Hsu, C.-C., Bonnen, P. E., Placzek, A. N., Sidrauski, C., Krnjević, K., Kaufman, R. J., Walter, P., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3754 · Cited by 201
Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.064 · Cited by 201
Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism
Huber, K. M., Klann, E., Costa-Mattioli, M., & Zukin, R. S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2656-15.2015 · Cited by 167
What Can We Learn about Autism from Studying Fragile X Syndrome?
Budimirovic, D. B., & Kaufmann, W. E. (2011) · Developmental Neuroscience · doi:10.1159/000330213 · Cited by 187
Hays, S. A., Huber, K. M., & Gibson, J. R. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3157-11.2011 · Cited by 163
Ebrahimi‐Fakhari, D., & Şahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 177
Borrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 169
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 157
Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology
Udagawa, T., Farny, N. G., Jakovcevski, M., Kaphzan, H., Alarcón, J. M., Anilkumar, S., Ivshina, M. P., Hurt, J. A., Nagaoka, K., Nalavadi, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3353 · Cited by 134
Myrick, L. K., Deng, P.-Y., Hashimoto, H., Oh, Y. M., Cho, Y., Poidevin, M. J., Suhl, J. A., Visootsak, J., Cavalli, V., Jin, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423094112 · Cited by 133
Hamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., & Ferguson, S. S. G. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-40 · Cited by 138
Synaptic retinoic acid signaling and homeostatic synaptic plasticity
Chen, L., Lau, A. G., & Sarti, F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.004 · Cited by 134
Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background
Ding, Q., Sethna, F., & Wang, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.046 · Cited by 131
Gross, C., Chang, C.-W., Kelly, S. M., Bhattacharya, A., McBride, S. M. J., Danielson, S. W., Jiang, M. Q., Chan, C. B., Ye, K., Gibson, J. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.060 · Cited by 117
Of Men and Mice: Modeling the Fragile X Syndrome
Dahlhaus, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00041 · Cited by 133
New perspectives on the biology of fragile X syndrome
Wang, T., Bray, S. M., & Warren, S. T. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.002 · Cited by 116
Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTor
Oguro-Ando, A., Rosensweig, C., Herman, E., Nishimura, Y., Werling, D., Bill, B. R., Berg, J. M., Gao, F., Coppola, G., Abrahams, B. S., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.124 · Cited by 117
β−Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives
Wess, J., Oteng, A., Rivera‐Gonzalez, O., Gurevich, E. V., & Gurevich, V. V. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000302 · Cited by 116
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion
Tian, D., Stoppel, L. J., Heynen, A. J., Lindemann, L., Jaeschke, G., Mills, A. A., & Bear, M. F. (2015) · Nature Neuroscience · doi:10.1038/nn.3911 · Cited by 109
Self-citationGenetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model
Goebel‐Goody, S. M., Wilson‐Wallis, E. D., Royston, S., Tagliatela, S. M., Naegele, J. R., & Lombroso, P. J. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00781.x · Cited by 108
Human FMRP contains an integral tandem Agenet (Tudor) and KH motif in the amino terminal domain
Myrick, L. K., Hashimoto, H., Cheng, X., & Warren, S. T. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu586 · Cited by 122
Till, S. M., Asiminas, A., Jackson, A. D., Katsanevaki, D., Barnes, S. A., Osterweil, E. K., Bear, M. F., Chattarji, S., Wood, E. R., Wyllie, D. J. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv299 · Cited by 109
Self-citationBanerjee, A., Ifrim, M. F., Valdez‐Sinon, A. N., Raj, N., & Bassell, G. J. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.008 · Cited by 111
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Higashimori, H., Schin, C. S., Chiang, M. S. R., Morel, L., Shoneye, T. A., Nelson, D. L., & Yang, Y. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1069-16.2016 · Cited by 105
Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond
Groß, C., Berry‐Kravis, E., & Bassell, G. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.137 · Cited by 109
Fragile X Mental Retardation Protein (FMRP) controls diacylglycerol kinase activity in neurons
Tabet, R., Moutin, E., Becker, J. A. J., Heintz, D., Fouillen, L., Flatter, E., Krężel, W., Alunni, V., Koebel, P., Dembélé, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522631113 · Cited by 112
Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome
Thomson, S. R., Seo, S. S., Barnes, S. A., Louros, S. R., Muscas, M., Dando, O., Kirby, C., Wyllie, D. J. A., Hardingham, G. E., Kind, P. C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.013 · Cited by 100
Self-citationTargeted treatments for fragile X syndrome
Berry‐Kravis, E., Knox, A. T., & Hervey, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9074-7 · Cited by 108
Fragile X syndrome: From protein function to therapy
Bagni, C., & Oostra, B. A. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36241 · Cited by 110
ERK/MAPK signaling and autism spectrum disorders
Vithayathil, J., Pucilowska, J., & Landreth, G. E. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.008 · Cited by 104
Neuronal Autophagy and Neurodevelopmental Disorders
Lee, K., Hwang, S.-K., & Lee, J. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.3.133 · Cited by 101
Deregulated mTOR-mediated translation in intellectual disability
Troca-Marín, J. A., Alves-Sampaio, A., & Montesinos, M. L. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.01.005 · Cited by 109
Co-regulation of mRNA translation by TDP-43 and Fragile X Syndrome protein FMRP
Majumder, P., Chu, J.-F., Chatterjee, B., Swamy, K. B. S., & Shen, C.-K. J. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1603-8 · Cited by 100
D’Antoni, S., Spatuzza, M., Bonaccorso, C. M., Musumeci, S. A., Ciranna, L., Nicoletti, F., Huber, K. M., & Catania, M. V. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.003 · Cited by 97
Pucilowska, J., Vithayathil, J., Pagani, M., Kelly, C. L., Karlo, J. C., Robol, C., Morella, I., Gozzi, A., Brambilla, R., & Landreth, G. E. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0515-17.2018 · Cited by 92
Ménard, C., & Quirion, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028666 · Cited by 98
Santini, E., Huynh, T. N., Longo, F., Koo, S. Y., Mojica, E. S., D’Andrea, L., Bagni, C., & Klann, E. (2017) · Science Signaling · doi:10.1126/scisignal.aan0665 · Cited by 92
Plasticity of dendritic spines: Molecular function and dysfunction in neurodevelopmental disorders
Nishiyama, J. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12899 · Cited by 96
Ménard, C., & Quirion, R. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00182 · Cited by 93
A Subset of Autism-Associated Genes Regulate the Structural Stability of Neurons
Lin, Y., Frei, J. A., Kilander, M. B. C., Shen, W., & Blatt, G. J. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00263 · Cited by 97
Rare FMR1 gene mutations causing fragile X syndrome: A review
Sitzmann, A. F., Hagelstrom, R. T., Tassone, F., Hagerman, R. J., & Butler, M. G. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38504 · Cited by 91
Wang, X., Snape, M., Klann, E., Stone, J. G., Singh, A., Petersen, R. B., Castellani, R. J., Casadesús, G., Smith, M. A., & Zhu, X. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07722.x · Cited by 91
Species-conserved SYNGAP1 phenotypes associated with neurodevelopmental disorders
Kılınç, M., Creson, T. K., Rojas, C., Aceti, M., Ellegood, J., Vaissière, T., Lerch, J. P., & Rumbaugh, G. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.03.008 · Cited by 87
Doll, C. A., & Broadie, K. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00030 · Cited by 86
Santos, A. R., Kanellopoulos, A. K., & Bagni, C. (2014) · Learning & Memory · doi:10.1101/lm.035956.114 · Cited by 91
Deregulation of synaptic plasticity in autism
Hansel, C. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.02.003 · Cited by 90
Developmental studies in fragile X syndrome
Razak, K. A., Dominick, K. C., & Erickson, C. A. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09310-9 · Cited by 87
Convergence of Hippocampal Pathophysiology in Syngap +/− and Fmr1 −/ y Mice
Barnes, S. A., Wijetunge, L. S., Jackson, A. D., Katsanevaki, D., Osterweil, E. K., Komiyama, N. H., Grant, S. G. N., Bear, M. F., Nägerl, U. V., Kind, P. C., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1087-15.2015 · Cited by 84
Self-citationSawicka, K., Pyronneau, A., Chao, M., Bennett, M. V. L., & Zukin, R. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610812113 · Cited by 84
Chévere-Torres, I., Kaphzan, H., Bhattacharya, A., Kang, A., Maki, J. M., Gambello, M. J., Arbiser, J. L., Santini, E., & Klann, E. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.028 · Cited by 83
Wang, C.-C., Held, R. G., & Hall, B. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083941 · Cited by 90
Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome
Tang, B., Wang, T., Wan, H., Han, L., Qin, X., Zhang, Y., Wang, J., Yu, C., Berton, F., Francesconi, W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502258112 · Cited by 84
Blizinsky, K. D., Diaz-Castro, B., Forrest, M. P., Schürmann, B., Bach, A. P., Martin-de-Saavedra, M. D., Wang, L., Csernansky, J. G., Duan, J., & Penzes, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607014113 · Cited by 76
Perturbed proteostasis in autism spectrum disorders
Louros, S. R., & Osterweil, E. K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13723 · Cited by 89
Self-citationBonnycastle, K., Davenport, E. C., & Cousin, M. A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15035 · Cited by 78
mTOR and MAPK: from localized translation control to epilepsy
Pernice, H. F., Schieweck, R., Kiebler, M. A., & Popper, B. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0308-1 · Cited by 81
Asiminas, A., Jackson, A. D., Louros, S. R., Till, S. M., Spano, T., Dando, O., Bear, M. F., Chattarji, S., Hardingham, G. E., Osterweil, E. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0498 · Cited by 78
Self-citationImpaired Critical Period Plasticity in Primary Auditory Cortex of Fragile X Model Mice
Kim, H., Gibboni, R., Kirkhart, C., & Bao, S. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3246-12.2013 · Cited by 74
Bell, J. J. L., Rakhade, S. N., Klein, P., Obeid, M., Jackson, M. C., Joseph, A., & Jensen, F. E. (2013) · Epilepsia · doi:10.1111/epi.12378 · Cited by 79
SYNGAP1 mutations: Clinical, genetic, and pathophysiological features
Agarwal, M., Johnston, M. V., & Stafstrom, C. E. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.08.003 · Cited by 79
Kasri, N. N., Nakano-Kobayashi, A., & Aelst, L. V. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.001 · Cited by 74
Neurobiology of autism gene products: towards pathogenesis and drug targets
Kleijer, K. T. E., Schmeißer, M. J., Krueger‐Burg, D., Boeckers, T. M., Scheiffele, P., Bourgeron, T., Brose, N., & Burbach, J. P. H. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3403-3 · Cited by 80
Gross, C., Raj, N., Molinaro, G., Allen, A. G., Whyte, A. J., Gibson, J. R., Huber, K. M., Gourley, S. L., & Bassell, G. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.065 · Cited by 71
Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
De Rubeis, S., & Bagni, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9087-2 · Cited by 73
Deletion of Fmr1 alters function and synaptic inputs in the auditory brainstem
Rotschafer, S. E., Marshak, S., & Cramer, K. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117266 · Cited by 72
The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia
Enríquez-Barreto, L., & Morales, M. (2016) · Journal of Green Engineering · doi:10.1186/s40591-016-0047-9 · Cited by 73
Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study
Çaku, A., Pellerin, D., Bouvier, P., Riou, E., & Corbin, F. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36750 · Cited by 77
Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
Jacquemont, S., Pacini, L., Jønch, A. E., Cencelli, G., Rozenberg, I., He, Y., D’Andrea, L., Pedini, G., Eldeeb, M., Willemsen, R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy099 · Cited by 73
Pasciuto, E., Ahmed, T., Wahle, T., Gardoni, F., D’Andrea, L., Pacini, L., Jacquemont, S., Tassone, F., Balschun, D., Dotti, C. G., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.032 · Cited by 71
Shank mutant mice as an animal model of autism
Yoo, J., Bakes, J., Bradley, C. A., Collingridge, G. L., & Kaang, B. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0143 · Cited by 76
Nguyen, R. L., Medvedeva, Y. V., Ayyagari, T., Schmunk, G., & Gargus, J. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.003 · Cited by 71
Sanderson, T. M., Hogg, E. L., Collingridge, G. L., & Corrêa, S. A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13592 · Cited by 72
Groß, C., & Bassell, G. J. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00363 · Cited by 70
Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders
Domenici, M. R., Ferrante, A., Martire, A., Chiodi, V., Pepponi, R., Tebano, M. T., & Popoli, P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104338 · Cited by 74
Metadata
- Authors
- Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F.
- Affiliations
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bear, Mark F.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-11-17
- Volume
- 30
- Issue
- 46
- Pages
- 15616-15627
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC3400430
- OpenAlex
- W2092491372
- Cited by
- 384
- References
- 81
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 18 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 27 · 2019: 23 · 2018: 22 · 2017: 34 · 2016: 33 · 2015: 29 · 2014: 30 · 2013: 31 · 2012: 24
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Howard Hughes Medical Institute
- FRAXA Research Foundation
- Simons Foundation
- National Institute of Mental Health
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD046943)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- fragile X syndrome, FMRP, mGluR5, ERK1/2, protein synthesis, hippocampus, metabotropic glutamate receptors, mRNA translation, Fmr1 knockout mice, audiogenic seizures, mTOR, therapeutic target
- MeSH terms
- Animals, Disease Models, Animal, Fragile X Syndrome, Hippocampus, Isoenzymes, Male, Mice, Inbred C57BL, Pyridines, Protein Biosynthesis, Up-Regulation, Receptors, Metabotropic Glutamate, Mice, Knockout, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Mice, Fragile X Messenger Ribonucleoprotein 1, Fragile X Mental Retardation Protein, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
